Published in Nat Biotechnol on May 23, 2010
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38
Raising the bar for cancer therapy models. Nat Biotechnol (2010) 4.52
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov (2014) 2.44
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med (2015) 2.05
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med (2012) 1.84
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev (2013) 1.60
Quantification of murine pancreatic tumors by high-resolution ultrasound. Methods Mol Biol (2013) 1.45
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol (2012) 1.30
Functional specificity of ras isoforms: so similar but so different. Genes Cancer (2011) 1.30
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene (2014) 1.29
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One (2012) 1.27
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A (2011) 1.26
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res (2013) 1.24
Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) (2011) 1.22
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene (2012) 1.22
Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol (2014) 1.19
Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res (2010) 1.15
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med (2012) 1.14
Reappraising antiangiogenic therapy for breast cancer. Breast (2011) 1.12
New cast for a new era: preclinical cancer drug development revisited. J Clin Invest (2013) 1.11
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res (2013) 1.09
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
Targeting SOD1 reduces experimental non–small-cell lung cancer. J Clin Invest (2014) 1.07
Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle (2015) 1.05
Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res (2011) 1.02
Animal models and conserved processes. Theor Biol Med Model (2012) 0.99
Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. J Clin Invest (2014) 0.98
Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol (2013) 0.97
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet (2011) 0.96
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther (2013) 0.95
Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One (2011) 0.93
Genetically engineered mouse models of pancreatic cancer. Cancer J (2012) 0.93
GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech (2015) 0.92
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res (2013) 0.91
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci (2013) 0.91
Non-invasive molecular imaging for preclinical cancer therapeutic development. Br J Pharmacol (2013) 0.91
Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma. Sarcoma (2012) 0.90
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med (2015) 0.90
Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. Dis Model Mech (2011) 0.89
Lessons learned from radiation oncology clinical trials. Clin Cancer Res (2013) 0.89
Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. Bioessays (2011) 0.89
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol (2015) 0.87
Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. Sci Transl Med (2015) 0.87
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia (2012) 0.86
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. Oncologist (2012) 0.86
A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy. Theranostics (2015) 0.85
Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med (2015) 0.84
Pathogenesis of pancreatic cancer: lessons from animal models. Toxicol Pathol (2013) 0.84
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest (2013) 0.84
Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer (2012) 0.81
Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. World J Clin Oncol (2011) 0.81
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes Cancer (2011) 0.81
Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. Genes Dev (2016) 0.81
Accelerating cancer modeling with RNAi and nongermline genetically engineered mouse models. Cold Spring Harb Protoc (2013) 0.80
Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) (2015) 0.80
In vivo screening of S100B inhibitors for melanoma therapy. Methods Mol Biol (2013) 0.80
Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. Pancreas (2014) 0.80
REPLACR-mutagenesis, a one-step method for site-directed mutagenesis by recombineering. Sci Rep (2016) 0.78
Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. Transl Oncol (2015) 0.78
Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett (2015) 0.78
Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol (2013) 0.78
Cancer: Clinical trials unite mice and humans. Nature (2012) 0.78
Drugs for solid cancer: the productivity crisis prompts a rethink. Onco Targets Ther (2013) 0.78
Drug efficacy testing in mice. Curr Top Microbiol Immunol (2012) 0.78
Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77
Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech (2015) 0.76
Modeling follicular thyroid cancer for future therapies. Am J Cancer Res (2012) 0.76
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. Oncotarget (2016) 0.76
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget (2016) 0.76
Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Res (2015) 0.76
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene (2016) 0.75
Preclinical screening methods in cancer. Indian J Pharmacol (2016) 0.75
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Curr Protoc Pharmacol (2016) 0.75
Monitoring brain tumor vascular heamodynamic following anti-angiogenic therapy with advanced magnetic resonance imaging in mice. PLoS One (2014) 0.75
Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel. World J Gastroenterol (2014) 0.75
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. Oncotarget (2016) 0.75
A systems biology approach to personalizing therapeutic combinations. Cancer Discov (2013) 0.75
Mouse models of metastasis: progress and prospects. Dis Model Mech (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Random-effects models for longitudinal data. Biometrics (1982) 54.17
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Simultaneous inference in general parametric models. Biom J (2008) 23.64
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res (2000) 3.75
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci (2007) 3.52
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Cancer modeling in the modern era: progress and challenges. Cell (2002) 3.12
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol (2007) 2.93
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest (1998) 2.51
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res (2005) 1.94
K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol (2008) 1.78
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One (2008) 1.72
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
Endpoints for assessing drug activity in clinical trials. Oncologist (2008) 1.66
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer (2006) 1.61
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs (2004) 1.47
Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res (2006) 1.44
Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res (2009) 1.41
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol (2008) 1.39
A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res (2005) 1.34
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol (2008) 1.30
A new generation of mouse models of cancer for translational research. Clin Cancer Res (2006) 1.22
High-resolution X-ray microtomography for the detection of lung tumors in living mice. Neoplasia (2004) 1.19
Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol (2008) 1.16
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol (2009) 1.15
Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res (2005) 1.13
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther (2008) 1.04
Oncogenes come of age. Cold Spring Harb Symp Quant Biol (2005) 0.95
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer (2008) 0.90
Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Curr Opin Oncol (2008) 0.88
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome. Nat Genet (2004) 8.24
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci (2002) 5.28
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Bayesian compressive sensing using laplace priors. IEEE Trans Image Process (2010) 4.93
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Generation of a prostate from a single adult stem cell. Nature (2008) 3.46
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71
Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res (2007) 2.57
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med (2009) 2.42
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27
The Academy of Medical Royal Colleges' statement on clinical research in the UK. Lancet (2009) 2.23
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol (2004) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer. World J Surg (2013) 2.12
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res (2007) 1.90
Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res (2012) 1.76
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav (2002) 1.75
Steatohepatitis induced by intragastric overfeeding in mice. Hepatology (2005) 1.73
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol (2006) 1.68
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther (2006) 1.64
Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci (2008) 1.63
Real-time reverse transcriptase-polymerase chain reaction quantification of West Nile virus transmitted by Culex pipiens quinquefasciatus. Am J Trop Med Hyg (2004) 1.60
Global defects in collagen secretion in a Mia3/TANGO1 knockout mouse. J Cell Biol (2011) 1.58
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
PKC-delta and -epsilon regulate NF-kappaB activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol (2004) 1.55
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 1.55
ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther (2012) 1.55
Hedgehog signaling regulates the generation of ameloblast progenitors in the continuously growing mouse incisor. Development (2010) 1.55
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A (2007) 1.54
Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol (2004) 1.53
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res (2004) 1.49
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol (2005) 1.46
Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci U S A (2010) 1.45
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res (2006) 1.44
Diffusion-weighted MR imaging in normal human brains in various age groups. AJNR Am J Neuroradiol (2002) 1.43
The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res (2002) 1.42
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Inferring the functional effects of mutation through clusters of mutations in homologous proteins. Hum Mutat (2010) 1.41
[Usefulness of PSA and its fractions in the diagnosis of prostate cancer]. Med Clin (Barc) (2004) 1.39
Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus. Mol Cell Biol (2005) 1.39
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res (2004) 1.35
Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One (2010) 1.34
Neuropilin-1 expression in cancer and development. J Pathol (2011) 1.34
Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res (2012) 1.32
Host-detrimental role of Esx-1-mediated inflammasome activation in mycobacterial infection. PLoS Pathog (2010) 1.31
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem (2011) 1.30
Bivalent antibody phage display mimics natural immunoglobulin. J Immunol Methods (2004) 1.30
Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res (2010) 1.29
In situ validation of an intestinal stem cell signature in colorectal cancer. Gut (2012) 1.26
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res (2004) 1.25
Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells. J Biol Chem (2003) 1.25
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Mouse TU tagging: a chemical/genetic intersectional method for purifying cell type-specific nascent RNA. Genes Dev (2013) 1.24
3D micro-CT imaging of the postmortem brain. J Neurosci Methods (2008) 1.23
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med (2007) 1.22
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol (2006) 1.20
Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med (2004) 1.20